These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26458066)

  • 1. Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival.
    Nagai S; Mangus RS; Kubal CA; Ekser B; Fridell JA; Klingler KR; Maluccio MA; Tector AJ
    Clin Transplant; 2015 Dec; 29(12):1156-63. PubMed ID: 26458066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
    Na GH; Hong TH; You YK; Kim DG
    World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation.
    Nagai S; Abouljoud MS; Kazimi M; Brown KA; Moonka D; Yoshida A
    Transplantation; 2014 Mar; 97(6):694-701. PubMed ID: 24637868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a report of four cases.
    Hong YM; Yoon KT; Cho M; Kang DH; Kim HW; Choi CW; Park SB; Heo J; Woo HY; Lim W
    Korean J Gastroenterol; 2015 Apr; 65(4):246-51. PubMed ID: 25896160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection.
    Chan AW; Chan SL; Wong GL; Wong VW; Chong CC; Lai PB; Chan HL; To KF
    Ann Surg Oncol; 2015 Dec; 22(13):4138-48. PubMed ID: 25801356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
    Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
    Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
    Zhang W; Zhao G; Wei K; Zhang Q; Ma W; Wu Q; Zhang T; Kong D; Li Q; Song T
    Med Oncol; 2015 Apr; 32(4):107. PubMed ID: 25750040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
    de'Angelis N; Landi F; Nencioni M; Palen A; Lahat E; Salloum C; Compagnon P; Lim C; Costentin C; Calderaro J; Luciani A; Feray C; Azoulay D
    Prog Transplant; 2016 Dec; 26(4):348-355. PubMed ID: 27555074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
    de'Angelis N; Landi F; Carra MC; Azoulay D
    World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute lymphocyte count recovery at 1 month after transplantation predicts favorable outcomes of patients with hepatocellular carcinoma.
    Zheng Z; Lin B; Zhang J; Yang Z; Xie H; Zhou L; Zhang M; Zheng S
    J Gastroenterol Hepatol; 2015 Apr; 30(4):706-11. PubMed ID: 25238140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
    De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
    Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
    Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
    J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
    Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
    Howell J; Pinato DJ; Ramaswami R; Arizumi T; Ferrari C; Gibbin A; Burlone ME; Guaschino G; Toniutto P; Black J; Sellers L; Kudo M; Pirisi M; Sharma R
    Oncotarget; 2017 May; 8(22):36161-36170. PubMed ID: 28212535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and prognostic nutrition index as preoperative predictors of early mortality after liver resection for huge (≥10 cm) hepatocellular carcinoma.
    Goh BK; Kam JH; Lee SY; Chan CY; Allen JC; Jeyaraj P; Cheow PC; Chow PK; Ooi LL; Chung AY
    J Surg Oncol; 2016 May; 113(6):621-7. PubMed ID: 26861568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
    Pfeiffenberger J; Koschny R; Hoffmann K; Mehrabi A; Schmitz A; Radeleff B; Stremmel W; Schemmer P; Ganten TM
    Langenbecks Arch Surg; 2013 Dec; 398(8):1123-8. PubMed ID: 24091908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
    Alsina AE; Makris A; Nenos V; Sucre E; Arrobas J; Franco E; Kemmer N
    Am Surg; 2014 Jul; 80(7):680-4. PubMed ID: 24987900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
    Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
    Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.